Email this page
Print
Bookmark and share
Bigger
Smaller
RSS feedFor consumers
(1300 633 424)
Mon-Fri | 9am-5pm AEST
Your call will be answered by healthdirect Australia
For health professionals
Find out the active ingredient and other brand names of your medicines with the NPS Medicine Name Finder
For a medicinewise Australia
Independent. Not-for-profit. Evidence based.
Site Tools
Quick Links
Articles on Avandia (rosiglitazone) from NPS RADARArticles on Avandia (rosiglitazone) from NPS RADAR
| Title | Content Type | Date | Description |
|---|---|---|---|
| Rosiglitazone (Avandia) and rosiglitazone with metformin (Avandamet) for type 2 diabetes mellitus | Professional publication - NPS RADAR - Review | 2008-12-01 00:00:00 | Rosiglitazone improves glycaemic control but there is a lack of evidence that it improves diabetes–related clinical complications and mortality. Rosiglitazone is no longer indicated in combination with insulin or for triple oral therapy in combination with metformin and a sulfonylurea. Rosiglitazone is a third-line choice. It may still be considered as part of dual therapy when either metformin or a sulfonylurea is contraindicated or not tolerated. Insulin should also be considered instead of rosiglitazone in these scenarios. Do not use rosiglitazone in people with heart failure or a history of heart failure. |
| Rosiglitazone and cardiovascular risk - NPS fact sheet | Professional publication - NPS RADAR - Brief item | 2007-08-01 00:00:00 | NPS has released a fact sheet discussing a recent meta-analysis that has raised concerns about a potential increase in cardiovascular risk among patients treated with rosiglitazone. |
| Pioglitazone (Actos) and rosiglitazone (Avandia) authority wording changed | Professional publication - NPS RADAR - Brief item | 2006-08-01 00:00:00 | The wording of the PBS requirements for pioglitazone (Actos) and rosiglitazone (Avandia) changed on 1 August 2006. The changes are intended to simplify the listings, and there are no changes to the authority requirements. |
View all RADAR articles by date, by therapeutic topic, or by active ingredient, or find out more about NPS RADAR.
NPS RADAR: independent, evidence-based assessment of new drugs, new PBS listings and the latest research for doctors, pharmacists and other health professionals.
Date published: 2009-10-30 00:00:00
Reasonable care is taken to provide accurate information at the date of creation. This information is not intended as a substitute for medical advice from a qualified health professional. Health professionals should rely on their own expertise and enquiries when providing medical advice or treatment. Where permitted by law, NPS disclaims all liability (including for negligence) for any loss, damage or injury resulting from reliance on or use of this information. Read our full disclaimer.
References to brands should not be taken as an endorsement by NPS.
